Phibro Animal Health Corp. (NASDAQ:PAHC) saw strong trading volume on Monday . 61,211 shares traded hands during trading, a decline of 7% from the previous session’s volume of 65,974 shares.The stock last traded at $21.02 and had previously closed at $20.80.

A number of equities analysts have issued reports on the company. Zacks Investment Research upgraded Phibro Animal Health Corp. from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 12th. TheStreet downgraded Phibro Animal Health Corp. from a “hold” rating to a “sell” rating in a research report on Thursday, June 9th. Guggenheim reissued a “buy” rating and set a $26.00 target price (down previously from $34.00) on shares of Phibro Animal Health Corp. in a report on Friday, May 13th. Finally, Morgan Stanley reissued a “sell” rating on shares of Phibro Animal Health Corp. in a report on Thursday, May 12th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $35.33.

The company’s 50 day moving average is $20.58 and its 200-day moving average is $22.59. The company has a market capitalization of $829.52 million and a PE ratio of 10.79.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 28th. Investors of record on Wednesday, September 7th will be given a $0.10 dividend. This represents a $0.40 annualized dividend and a yield of 1.90%. The ex-dividend date is Friday, September 2nd.

Phibro Animal Health Corporation is an animal health and mineral nutrition company. The Company is engaged in developing, manufacturing and marketing products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. The Company operates through three segments: Animal Health, Mineral Nutrition and Performance Products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.